Skip to Main Content

Paper Details

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Clin Cancer Res
36
2023
Cas9, EV, Enfortumab Vedotin, MET, NECTIN-4, NECTIN-4 protein, NECTIN-4 receptor, PRIM, Urothelial Carcinoma, enfortumab vedotin, mUC, metastatic urothelial carcinoma, patient, patients, primary tumors, tumor, tumor cells
Author NameAffiliation
Bernd Wullich
Bernd WullichComprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg
Bernd WullichUniversity Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Bernd WullichBavarian Center for Cancer Research (Bayerisches Zentrum fur Krebsforschung
Bernd Wullich
Bernd WullichComprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg
Bernd WullichUniversity Hospital Erlangen, Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU)
Bernd WullichBavarian Center for Cancer Research (Bayerisches Zentrum fur Krebsforschung
  • 1 - 8

Datasets

Release 1.2